Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)
ID: 337926Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)" aimed at supporting innovative research on brain and nervous system disorders relevant to low- and middle-income countries (LMICs). This initiative encourages collaborative projects between U.S. and LMIC scientists, focusing on a range of neurological, mental, and behavioral disorders, and aims to enhance research capacity in resource-constrained environments. Eligible applicants include various institutions such as higher education entities, nonprofits, and government agencies from both the U.S. and LMICs, with an emphasis on interdisciplinary approaches that consider socio-economic factors. The application deadline is December 9, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-097.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services is issuing a Funding Opportunity Announcement (FOA) to support innovative research on brain and nervous system disorders relevant to Low and Middle-Income Countries (LMICs). This initiative, through the National Institutes of Health (NIH), aims to foster collaborative projects that enhance neuro-health research capacity and address the burden of neurological disorders across the lifespan. It encourages applications from both U.S. and LMIC institutions, emphasizing the need for studies on neurological, neurodevelopmental, and neuropsychiatric conditions. Eligible entities include higher education institutions, nonprofits, and government agencies from LMICs and the U.S., with a focus on building sustainable research infrastructure. The application process allows various project types, including those involving clinical trials. A significant emphasis is placed on interdisciplinary approaches that incorporate socio-economic factors and local contexts to improve treatment and intervention strategies. Key deadlines for application submission are specified, alongside guidelines for budgeting, eligibility, and required formats. The FOA encourages applicants to engage in preliminary collaborations and consultations to ensure relevance to the research priorities of participating NIH Institutes. This funding opportunity reflects a commitment to global health advancement by establishing necessary research frameworks in resource-constrained environments.
    Similar Opportunities
    Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)" aimed at fostering exploratory and developmental research on brain and nervous system disorders, particularly in low- and middle-income countries (LMICs). This initiative encourages collaborative research projects that span the life cycle and address the increasing burden of neurological conditions, with a focus on building sustainable research capacity and developing culturally appropriate diagnostic and treatment strategies. Eligible applicants include a diverse range of organizations, such as historically black colleges and universities, tribal governments, and foreign entities, with no cost-sharing requirement. The application deadline is December 9, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-098.html.
    Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Consortium for Neuroscience AD/ADRD in Low- and Middle-Income Countries," aimed at fostering collaborative research on Alzheimer's disease (AD) and related dementias (ADRD) in low- and middle-income countries (LMICs). This initiative seeks to build sustainable neuroscience research capacity by encouraging partnerships between U.S. researchers and scientists from LMICs, focusing on population-relevant studies that address the unique epidemiological and risk factors associated with AD/ADRD in diverse populations. The program will provide a total of $2.16 million for up to five awards, with individual application budgets capped at $400,000 annually over a five-year period. Interested applicants must submit their proposals by February 14, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Engineering Next-Generation Human Nervous System Microphysiological Systems (R01 Clinical Trials Not Allowed)," aimed at advancing research in human cell-derived microphysiological systems (MPS) that replicate complex nervous system architectures and functions. This initiative seeks innovative applications that address technological barriers in studying nervous system development and diseases, with a focus on improving physiological relevance and circuit-level activity in existing assays. The funding is open to a wide range of eligible applicants, including higher education institutions and non-profits, with a project period of up to five years and no cost-sharing requirement. Interested parties should note that the application deadline is January 7, 2026, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the announcement page at https://grants.nih.gov/grants/guide/pa-files/PAR-23-046.html.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    Coordinating Center to Support Consortium for Neuroscience Alzheimers Disease (AD) and AD-Related Dementias (ADRD) Research in Low- and Middle-Income Countries (LMICs) (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for a Coordinating Center to support research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Low- and Middle-Income Countries (LMICs) through a U24 Cooperative Agreement. The primary objective of this initiative is to enhance collaboration among researchers by providing administrative coordination, stakeholder engagement, and facilitating data sharing in accordance with NIH policies, thereby addressing the growing burden of AD/ADRD in these regions. This funding opportunity is crucial for improving research accessibility and fostering sustainable programs that can lead to effective prevention and treatment strategies tailored to LMIC populations. Interested applicants can apply for a budget of up to $560,000, with proposals due by 5:00 PM on November 14, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research on the biological mechanisms underlying complex brain disorders such as schizophrenia, bipolar disorder, and autism. This initiative encourages studies that explore high-confidence risk factors associated with these disorders, focusing on intracellular, transcellular, and circuit mechanisms, while emphasizing the importance of disseminating findings to enhance data resources and therapeutic target identification. Eligible applicants include a wide range of institutions, including historically black colleges, tribal colleges, and various nonprofit organizations, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and detailed information can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-024.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.